LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. grew its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 113.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,093 shares of the medical instruments supplier’s stock after purchasing an additional 12,797 shares during the period. Harbor Capital Advisors Inc. owned approximately 0.11% of LeMaitre Vascular worth $2,238,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. F M Investments LLC increased its stake in LeMaitre Vascular by 36.6% in the 3rd quarter. F M Investments LLC now owns 123,545 shares of the medical instruments supplier’s stock valued at $11,476,000 after buying an additional 33,087 shares during the period. James Investment Research Inc. acquired a new position in shares of LeMaitre Vascular during the third quarter worth about $201,000. Conestoga Capital Advisors LLC raised its holdings in LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after purchasing an additional 36,850 shares in the last quarter. Oak Ridge Investments LLC acquired a new stake in LeMaitre Vascular in the third quarter valued at about $2,020,000. Finally, Rice Hall James & Associates LLC boosted its holdings in LeMaitre Vascular by 15.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock valued at $24,273,000 after purchasing an additional 35,383 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.79% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on LMAT. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Oppenheimer restated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday. JMP Securities raised their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Performance

LMAT stock opened at $96.35 on Tuesday. The stock’s 50 day moving average price is $89.70 and its 200 day moving average price is $83.49. The firm has a market cap of $2.16 billion, a P/E ratio of 52.65, a PEG ratio of 2.32 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1 year low of $47.72 and a 1 year high of $101.67.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.39% and a net margin of 19.40%. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.33 earnings per share. On average, research analysts predict that LeMaitre Vascular, Inc. will post 1.86 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.66%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.